Perrotta FM, et al. - Herein, the experts aimed to assess the residual disease activity (RDA) and function in rheumatoid arthritis (RA) subjects treated with subcutaneous biologic drugs that according to the various indices validated for RA, gained a status of remission and low disease activity (LDA). They also gauged the factors related to RDA. Data suggested that in LDA, up to one-fourth of cases and about one-fifth of patients in remission had a residual functional impairment with HAQ score more than 0.5. RDA in RA was noted even in subjects with remission or LDA, especially for the reported outcome of the patients. In a significant rate of patients, an impaired function was also present.